Molecule-level and market-level profitability analysis across domestic, export, API,
Molecule-level and market-level profitability analysis across domestic, export, API, and CDMO businesses
Product-wise margin analysis, R&D capitalisation and amortisation, regulatory filing cost tracking, distribution channel ROI, and clinical-trial budget management for pharma and life sciences companies.
Pharmaceutical economics operate on long, uncertain arcs. R&D and regulatory investments — filings, plant approvals, bioequivalence studies — are committed years ahead of revenue, against approval probabilities that demand portfolio thinking rather than project optimism. Margins vary enormously by molecule, market, and channel: domestic branded generics, export generics, API, CDMO, and licensing each carry distinct economics. API cost volatility and import dependence squeeze gross margins; regulatory remediation can idle capacity overnight. Field-force productivity and channel inventories drive domestic performance. Finance in this industry must think in portfolios, probabilities, and decade-long horizons — while controlling cost this quarter.
Leading pharma companies manage the portfolio on probability-adjusted economics: molecule-level margins, rNPV-ranked pipelines, capacity decisions tied to regulatory and demand scenarios, and field-force productivity measured with sales-force-effectiveness rigour. Channel inventory is governed, not guessed.
Portfolio discipline concentrates R&D and capacity capital on the molecules and markets with the best risk-adjusted returns — building a pipeline whose value compounds and a P&L that funds it.